Compare UNM & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UNM | BMRN |
|---|---|---|
| Founded | 1848 | 1996 |
| Country | United States | United States |
| Employees | 10910 | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 10.0B |
| IPO Year | N/A | 1999 |
| Metric | UNM | BMRN |
|---|---|---|
| Price | $75.29 | $55.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 17 |
| Target Price | ★ $94.27 | $87.24 |
| AVG Volume (30 Days) | 1.4M | ★ 1.9M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.80 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | N/A | $13.34 |
| Revenue Next Year | $4.84 | $11.42 |
| P/E Ratio | ★ $17.16 | $32.34 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $66.81 | $50.76 |
| 52 Week High | $84.48 | $73.18 |
| Indicator | UNM | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 57.56 | 34.51 |
| Support Level | $72.54 | $52.30 |
| Resistance Level | $79.92 | $56.89 |
| Average True Range (ATR) | 2.17 | 2.08 |
| MACD | 0.31 | -0.64 |
| Stochastic Oscillator | 97.74 | 4.37 |
Unum Group is a provider of group and individual income protection insurance products in the United States, the United Kingdom, Poland, and other countries. It is the domestic disability insurer, with the majority of premiums generated from employer plans. The company also offers a complementary portfolio of other insurance products, including long-term care insurance, life insurance, and employer- and employee-paid group benefits. It has the following operating business segments: Unum USA, Unum International, Closed Block, Colonial Life, and Corporate. The Unum USA segment generates the majority of revenue. The firm markets its products through brokers.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.